Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani

Vaccine

Volumn 19, Issue 23-24, 2001, Pages 3104-3115

  Paraguai de Souza, Edilma ^a   Bernardo, Robson Roney ^b   Palatnik, Marcos ^a   Palatnik de Sousa, Clarisa Beatriz ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Departamento de Processos Inorgânicos   (Brazil)

Author keywords

Adjuvants; GP36 glycoprotein; Murine visceral leishmaniasis; Native antigen; Saponin

Indexed keywords

ANTIGEN; GLYCOPROTEIN; GLYCOPROTEIN GP36; SAPONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFECT; GANGLION; LIVER; LYMPHOCYTE; MOUSE; NONHUMAN; PARASITE; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN ISOLATION; VISCERAL LEISHMANIASIS;

EID: 0035971970     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00031-7     Document Type: Article

References (54)

1. Tropical disease research progress 1997-1998. Leishmaniasis. Fourteenth programme report
2. Control of zoonotic visceral leishmaniasis. Is it time to change strategies?
3. Controlled field trials of a vaccine against New World cutaneous leishmaniasis
4. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: Skin-test reactivity, T-cell proliferation and interferon-γ production
5. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran
6. Double targeted gene replacement for creating null mutants
7. Development of a safe live Leishmania vaccine line by gene replacement
8. Null mutants for the lmcpa cysteine proteinase gene in Leishmania mexicana
9. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis
10. Recombinant vaccinia viruses expressing GP-46/M-2 protect against Leishmania infection
11. Human T cell responses to gp63, a surface antigen of Leishmania
12. Subunit vaccination of mice against New World cutaneous leishmaniasis: Comparison of three proteins expressed in amastigotes and six adjuvants
13. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine
14. Shared antigens between Leishmania and Trypanosoma cruzi: Characterization of the Leishmania chagasi acidic ribosomal protein PO
15. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania donovani
16. Effective immunization against cutaneous Leishmaniasis with defined membrane antigens reconstituted into liposomes
17. Lipophosphoglycan of Leishmania major that vaccinates against Cutaneous Leishmaniasis contains alkylglycerol phosphoinositol lipid anchor
18. The Leishmania donovani lipophosphoglycan T lymphocyte reactive component is a tightly associated protein complex
19. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis
20. Genetic vaccination against leishmaniasis
21. Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate
22. Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the Fucose-Mannose Ligand (FML)
23. A new approach to phylogeny of Leishmania: Species-specificity of glycoconjugate ligands for promastigote internalization into murine macrophages
24. Experimental murine Leishmania donovani infection immunoprotection by the Fucose Mannose Ligand (FML)
25. Vaccination with the FML antigen (Fucose Mannose Ligand) of Leishmania donovani in the Swiss Albino model
26. Leishmania donovani: Titration of antibodies to the Fucose Mannose Ligand as an aid in diagnosis and prognosis of visceral leishmaniasis
27. The FML-ELISA assay in diagnosis and prognosis of canine visceral leishmaniasis
28. Adjuvant requirement for protective immunization of mice using Trypanosoma cruzi 90K cell surface glycoprotein, Int
29. Formulation of an immunogenic human cytomegalovirus vaccine: Response in mice
30. A purified parasite antigen (p30) mediates CD8 + T cell immunity against fatal Toxoplasma gondii infection in mice
31. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection
32. Adjuvanticity and ISCOMs formation by structurally diverse saponins
33. Novel adjuvants currently in clinical testing. November 2-4, 1998, Foundation Mérieux, Annency, France: A Meeting sponsored by the World Health Organization. Meeting Report
34. The FML vaccine (Fucose-Mannose Ligand) protects hamsters from experimental Kala-Azar
35. The FML (Fucose Mannose Ligand) of Leishmania donovani. A new tool in diagnosis, prognosis, transfusional control and vaccination against human Kala-Azar
36. An improved method for the isolation of erythrocyte antigen band-3
37. Differential production of TH1- and TH2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis
38. Regulation of Leishmania population within the host. The variable course of Leishmania donovani infections in the mice
39. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
40. Student's t test of significance
41. Detection of monoclonal antibodies specific for carbohydrate epitopes using periodate oxidation
42. Structure studies and surface glycoproteins of Leishmania promastigotes: Isolation, aminoacid composition and aminoterminal sequence studies
43. Role of mannose receptors in the ingestion of Leishmania donovani by human macrophages
44. Roles of CR3 and mannose receptors in the attachment and ingestion of Leishmania donovani by human mononuclear phagocytes
45. The control of the antibody isotype response to recombinant immunodeficiency virus gp120 antigen by adjuvants
46. Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi
47. A comparison of saponin with other adjuvants for the potentiation of protective immunity by a killed Plasmodium yoelii vaccine in the mouse
48. Saponin adjuvant primes for a dominant interleukin 10 production to ovalbumin and to Trypanosoma cruzi antigen
49. Antigen-specific immunosupression in visceral leishmaniasis is cell mediated
50. Cell mediated immune response in Indian kala-azar and post kala-azar dermal leishmaniasis
51. Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine
52. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis
53. The genetics of susceptibility and resistance in the vertebrate host
54. Fatal visceral leishmaniasis in a strain of Swiss mice